Molecular Mechanisms of Resveratrol (3,4,5-trihydroxy-trans-stilbene) and Its Interaction with TNF-related Apoptosis Inducing Ligand (TRAIL) in Androgen-insensitive Prostate Cancer Cells

Overview

Journal Mol Cell Biochem

Publisher Springer

Specialty Biochemistry

Date 2007 Jul 20

PMID 17636462

Citations 45

Authors

Sharmila Shankar

Imtiaz Siddiqui

Rakesh K Srivastava

Affiliations

Soon will be listed here.

Abstract

Although resveratrol, an active ingredient derived from grapes and red wine, possesses chemopreventive properties against several cancers, the molecular mechanisms by which it inhibits cell growth and induces apoptosis have not been clearly understood. Here, we examined the molecular mechanisms of resveratrol and its interactive effects with TRAIL on apoptosis in prostate cancer PC-3 and DU-145 cells. Resveratrol inhibited cell viability and colony formation, and induced apoptosis in prostate cancer cells. Resveratrol downregulated the expression of Bcl-2, Bcl-X(L) and survivin and upregulated the expression of Bax, Bak, PUMA, Noxa, and Bim, and death receptors (TRAIL-R1/DR4 and TRAIL-R2/DR5). Treatment of prostate cancer cells with resveratrol resulted in generation of reactive oxygen species (ROS), translocation of Bax to mitochondria and subsequent drop in mitochondrial membrane potential, release of mitochondrial proteins (cytochrome c, Smac/DIABLO, and AIF) to cytosol, activation of effector caspase-3 and caspase-9, and induction of apoptosis. Resveratrol-induced ROS production, caspase-3 activity and apoptosis were inhibited by N-acetylcysteine. Bax was a major proapoptotic gene mediating the effects of resveratrol as Bax siRNA inhibited resveratrol-induced apoptosis. Resveratrol enhanced the apoptosis-inducing potential of TRAIL, and these effects were inhibited by either dominant negative FADD or caspase-8 siRNA. The combination of resveratrol and TRAIL enhanced the mitochondrial dysfunctions during apoptosis. These properties of resveratrol strongly suggest that it could be used either alone or in combination with TRAIL for the prevention and/or treatment of prostate cancer.

Citing Articles

Phytochemicals as Immunomodulatory Molecules in Cancer Therapeutics.

Paudel S, Mishra N, Agarwal R Pharmaceuticals (Basel). 2023; 16(12).

PMID: 38139779 PMC: 10746110. DOI: 10.3390/ph16121652.

Pharmacological Small Molecules against Prostate Cancer by Enhancing Function of Death Receptor 5.

Gan X, Liu Y, Wang X Pharmaceuticals (Basel). 2022; 15(8).

PMID: 36015177 PMC: 9413322. DOI: 10.3390/ph15081029.

Harnessing TRAIL-Induced Apoptosis Pathway for Cancer Immunotherapy and Associated Challenges.

Razeghian E, Suksatan W, Rahman H, Bokov D, Abdelbasset W, Hassanzadeh A Front Immunol. 2021; 12:699746.

PMID: 34489946 PMC: 8417882. DOI: 10.3389/fimmu.2021.699746.

The Impact of obesity and diabetes mellitus on pancreatic cancer: Molecular mechanisms and clinical perspectives.

Lam B, Shrivastava S, Shrivastava A, Shankar S, Srivastava R J Cell Mol Med. 2020; 24(14):7706-7716.

PMID: 32458441 PMC: 7348166. DOI: 10.1111/jcmm.15413.

Potential health benefits of phenolic compounds in grape processing by-products.

Averilla J, Oh J, Kim H, Kim J, Kim J Food Sci Biotechnol. 2019; 28(6):1607-1615.

PMID: 31807333 PMC: 6859169. DOI: 10.1007/s10068-019-00628-2.

References

Bhat K, Lantvit D, Christov K, Mehta R, Moon R, Pezzuto J . Estrogenic and antiestrogenic properties of resveratrol in mammary tumor models. Cancer Res. 2001; 61(20):7456-63. View

Kannan , Jain . Oxidative stress and apoptosis. Pathophysiology. 2000; 7(3):153-163. DOI: 10.1016/s0928-4680(00)00053-5. View

Agarwal R . Cell signaling and regulators of cell cycle as molecular targets for prostate cancer prevention by dietary agents. Biochem Pharmacol. 2000; 60(8):1051-9. DOI: 10.1016/s0006-2952(00)00385-3. View

Pan G, ORourke K, Chinnaiyan A, Gentz R, Ebner R, Ni J . The receptor for the cytotoxic ligand TRAIL. Science. 1997; 276(5309):111-3. DOI: 10.1126/science.276.5309.111. View

Srivastava R, Sasaki C, Hardwick J, Longo D . Bcl-2-mediated drug resistance: inhibition of apoptosis by blocking nuclear factor of activated T lymphocytes (NFAT)-induced Fas ligand transcription. J Exp Med. 1999; 190(2):253-65. PMC: 2195578. DOI: 10.1084/jem.190.2.253. View

Sheridan J, Marsters S, Pitti R, Gurney A, Skubatch M, Baldwin D . Control of TRAIL-induced apoptosis by a family of signaling and decoy receptors. Science. 1997; 277(5327):818-21. DOI: 10.1126/science.277.5327.818. View

Eiben L, Duckett C . The IAP family of apoptotic regulators. Results Probl Cell Differ. 1999; 24:91-104. DOI: 10.1007/978-3-540-69185-3_5. View

Duchen M . Mitochondria in health and disease: perspectives on a new mitochondrial biology. Mol Aspects Med. 2004; 25(4):365-451. DOI: 10.1016/j.mam.2004.03.001. View

Landis S, Murray T, Bolden S, Wingo P . Cancer statistics, 1999. CA Cancer J Clin. 1999; 49(1):8-31, 1. DOI: 10.3322/canjclin.49.1.8. View

10.

Shankar S, Singh T, Fandy T, Luetrakul T, Ross D, Srivastava R . Interactive effects of histone deacetylase inhibitors and TRAIL on apoptosis in human leukemia cells: involvement of both death receptor and mitochondrial pathways. Int J Mol Med. 2005; 16(6):1125-38. View

11.

Kandasamy K, Srinivasula S, Alnemri E, Thompson C, Korsmeyer S, Bryant J . Involvement of proapoptotic molecules Bax and Bak in tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-induced mitochondrial disruption and apoptosis: differential regulation of cytochrome c and Smac/DIABLO release. Cancer Res. 2003; 63(7):1712-21. View

12.

Letai A, Bassik M, Walensky L, Sorcinelli M, Weiler S, Korsmeyer S . Distinct BH3 domains either sensitize or activate mitochondrial apoptosis, serving as prototype cancer therapeutics. Cancer Cell. 2002; 2(3):183-92. DOI: 10.1016/s1535-6108(02)00127-7. View

13.

Murphy E, Imahashi K, Steenbergen C . Bcl-2 regulation of mitochondrial energetics. Trends Cardiovasc Med. 2005; 15(8):283-90. DOI: 10.1016/j.tcm.2005.09.002. View

14.

Kuwana T, Newmeyer D . Bcl-2-family proteins and the role of mitochondria in apoptosis. Curr Opin Cell Biol. 2003; 15(6):691-9. DOI: 10.1016/j.ceb.2003.10.004. View

15.

Levine B, Goldman J, Jiang H, Griffin D, Hardwick J . Bc1-2 protects mice against fatal alphavirus encephalitis. Proc Natl Acad Sci U S A. 1996; 93(10):4810-5. PMC: 39361. DOI: 10.1073/pnas.93.10.4810. View

16.

Singh T, Shankar S, Srivastava R . HDAC inhibitors enhance the apoptosis-inducing potential of TRAIL in breast carcinoma. Oncogene. 2005; 24(29):4609-23. DOI: 10.1038/sj.onc.1208585. View

17.

Azam S, Hadi N, Khan N, Hadi S . Prooxidant property of green tea polyphenols epicatechin and epigallocatechin-3-gallate: implications for anticancer properties. Toxicol In Vitro. 2004; 18(5):555-61. DOI: 10.1016/j.tiv.2003.12.012. View

18.

Srivastava R . TRAIL/Apo-2L: mechanisms and clinical applications in cancer. Neoplasia. 2002; 3(6):535-46. PMC: 1506567. DOI: 10.1038/sj.neo.7900203. View

19.

Green D, Reed J . Mitochondria and apoptosis. Science. 1998; 281(5381):1309-12. DOI: 10.1126/science.281.5381.1309. View

20.

Green D, Kroemer G . The pathophysiology of mitochondrial cell death. Science. 2004; 305(5684):626-9. DOI: 10.1126/science.1099320. View